Four-ring Pharmaceuticals (00460.HK): Two indications for Xuanzhu Bioscience's independently developed innovative drug, piroselipin single drug and combined with fluorovis group for the treatment of HR+/HER2- advanced breast cancer, have been approved by the National Medical Products Administration for market listing.

Wealth Magazine APP news, Sihuan Pharmaceutical (00460.HK) announced that the new drug Pyroxiciliban (formerly known as "Pirocicin", XZP-3287, trade name: Xuan Yuening) developed independently by its non-wholly owned subsidiary Xuanzhu Biological Technology Co., Ltd. (Xuanzhu Biological) CDK4/6 (Cyclin-dependent kinase 4 and 6) inhibitor 1 type of new drug with 2 indications has obtained the drug registration certificate issued by the China National Medical Products Administration for the new drug application (NDA).